Save Product
Product Details
Source
The antibody is isolated from the serum of COVID-19 vaccine recipient and is recombinantly produced from human 293 cells (HEK293). This antibody can broadly neutralize SARS-CoV-2 Variants of Concerns (VOCs) including Alpha, Beta, Gamma, Delta and Omicron.
Antibody Type
Recombinant Monoclonal
Clone
AM359b
Isotype
Human IgG4, Kappa
Specificity
This product is a specific antibody against SARS-CoV-2 Spike protein RBD domain. Cross-reactivity with Spike protein RBD domain of other coronaviruses, including SARS-CoV, MERS-CoV, HCoV-229E, HCoV-NL63, HCoV-OC43 and HCoV-HKU1 has not been tested.
Purification
Protein A purified / Protein G purified.
Aggregation
Less than 10%, as determined by SEC-MALS.
Concentration
Please refer to the Certificate of Analysis (CoA).
Form
Lyophilized
Formulation
Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.
Please contact us for customized product forms or formulations.
Reconstitution
Please refer to the Certificate of Analysis (CoA) for specific instructions.
Shipping
Lyophilized product is shipped at ambient temperature.
Storage
For long term storage, the product should be stored in a lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Notices
Product Specific Notices: For research use only.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Bioactivity-ELISA
Immobilized SARS-CoV-2 Spike Trimer, His Tag (B.1.1.529/Omicron) (Cat. No. SPN-C52Hz) at 2μg/mL (100μL/well) can bind Anti-SARS-CoV-2 Spike RBD Broadly Neutralizing Antibody, Human IgG4 (AM359b) (Cat. No. SPD-M402a) with a linear range of 0.2-6 ng/mL (QC tested).
Protocol
Immobilized SARS-CoV-2 Spike RBD, His Tag (B.1.1.529/Omicron) (Cat. No. SPD-C522e) at 2μg/mL (100μL/well) can bind Anti-SARS-CoV-2 Spike RBD Broadly Neutralizing Antibody, Human IgG4 (AM359b) (Cat. No. SPD-M402a) with a linear range of 0.1-3 ng/mL (Routinely tested).
Protocol
Immobilized SARS-CoV-2 Spike protein WT (Cat. No. SPN-C52H9), Alpha (Cat. No. SPN-C52H6), Beta (Cat. No. SPN-C52Hk),Gamma (Cat. No. SPN-C52Hg), Delta (Cat. No. SPN-C52He) and Omicron (Cat. SPN-C52Hz) can bind Anti-SARS-CoV-2 Spike RBD Broadly Neutralizing Antibody, Human IgG4 (AM359b) (Cat. No. SPD-M402a) with a linear range of 0.20-6.25 ng/mL (Routinely tested).
Protocol
Immobilized SARS-CoV-2 Spike RBD WT (Cat. No. SPD-C52H1), Delta (Cat. No. SPD-C52Hh) and Omicron (Cat. SPD-C522e) can bind Anti-SARS-CoV-2 Spike RBD Broadly Neutralizing Antibody, Human IgG4 (AM359b) (Cat. No. SPD-M402a) with a linear range of 0.20-6.25 ng/mL (Routinely tested).
Protocol
Anti-SARS-CoV-2 Spike RBD Broadly Neutralizing Antibody, Human IgG4 (AM359b) (Cat.No. SPD-M402a) neutralizes SARS-CoV-2 Spike Trimer by inhibiting Spike: ACE2 interaction. The Wild type (WT) Spike Trimer or Alpha, Delta, B.1.1.529/Omicron, BA.2/Omicron, BA.3/Omicron mutant-coated plate is incubated with the Biotinylated Human ACE2 / ACEH Protein and treated with the neutralizing antibody at increasing concentration . Percent inhibition is calculated based on the OD value.
Protocol
Customer Reviews Writing Reviews
Background
Recent Advances
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
